Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis soars as Pfizer fronts $80m for immuno-oncology

This article was originally published in Scrip

Executive Summary

Pfizer is paying $80m up front to French company Cellectis for access to its CAR-T platform, an allogeneic cell therapy approach to treating cancer with the aim of developing 'off-the-shelf' immunotherapies. Cellectis's Chimeric Antigen Receptor T-cell (CAR-T) technology uses engineered T-cells from a single donor for use in multiple patients, compared with autologous approaches which require engineering of a patient's own T-cells to target tumor cells.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025588

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel